Literature DB >> 27117843

Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis.

R S Choung1, F Princen2, T P Stockfisch2, J Torres3, A C Maue4, C K Porter4, F Leon5, B De Vroey6, S Singh2, M S Riddle4, J A Murray1, J F Colombel3,7.   

Abstract

BACKGROUND: Patients with Crohn's disease (CD) have serologic responses to various microbial antigens. Serologic markers are associated with aggressive forms of disease and can be detected before onset of symptoms. Their utility in pre-clinical disease or prediction of complicated disease course before diagnosis is unclear. AIM: To evaluate the pattern of serologic anti-microbial antibodies long prior to diagnosis and the subsequent risk of complicated Crohn's disease at diagnosis.
METHODS: Sera from 100 US military personnel with Crohn's disease were obtained from the Department of Defense Serum Repository. For each patient, four samples were obtained at different time points before and around diagnosis, and were tested for 6 microbiota-directed antibodies (ASCA-IgA, ASCA-IgG, anti-OmpC, anti-CBir1, anti-A4-Fla2 and anti-FlaX). Associations between the presence and accumulation of Crohn's disease anti-microbial antibodies before diagnosis and with the later development of complications were evaluated.
RESULTS: Overall, 65 patients were positive for at least one Crohn's disease associated anti-microbial antibody in the earliest available sample, at a median of 6 years before Crohn's disease diagnosis (interquartile range, 5.6-8.2). The number of positive anti-microbial antibodies increased up to the time of Crohn's disease diagnosis. Complicated disease developed around the time of diagnosis in 24 patients. The proportion of positive antimicrobial antibodies before diagnosis was higher in patients with complicated vs. noncomplicated Crohn's disease. There was an inverse relationship between the time to first complication and the magnitude of serologic response before diagnosis.
CONCLUSION: The presence and accumulation of circulating anti-microbial antibodies years before Crohn's disease diagnosis was associated with complicated Crohn's disease at or shortly after diagnosis.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27117843     DOI: 10.1111/apt.13641

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  29 in total

1.  Editorial: Statins for Inflammatory Bowel Disease: Expanding the Scope of Prevention.

Authors:  Hamed Khalili
Journal:  Am J Gastroenterol       Date:  2016-10       Impact factor: 10.864

2.  Detectable Laboratory Abnormality Is Present up to 12 Months Prior to Diagnosis in Patients with Crohn's Disease.

Authors:  James R Irwin; Emma Ferguson; Lisa A Simms; Katherine Hanigan; James D Doecke; Daman Langguth; Ashley Arnott; Graham Radford-Smith
Journal:  Dig Dis Sci       Date:  2018-11-26       Impact factor: 3.199

Review 3.  The IBD interactome: an integrated view of aetiology, pathogenesis and therapy.

Authors:  Heitor S P de Souza; Claudio Fiocchi; Dimitrios Iliopoulos
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

Review 4.  New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes.

Authors:  Edward L Barnes; Robert Burakoff
Journal:  Inflamm Bowel Dis       Date:  2016-12       Impact factor: 5.325

Review 5.  Challenges in IBD Research: Environmental Triggers.

Authors:  Shuk-Mei Ho; James D Lewis; Emeran A Mayer; Scott E Plevy; Emil Chuang; Stephen M Rappaport; Kenneth Croitoru; Joshua R Korzenik; Jeffrey Krischer; Jeffrey S Hyams; Richard Judson; Manolis Kellis; Michael Jerrett; Gary W Miller; Melanie L Grant; Nataly Shtraizent; Gerard Honig; Andrés Hurtado-Lorenzo; Gary D Wu
Journal:  Inflamm Bowel Dis       Date:  2019-05-16       Impact factor: 5.325

Review 6.  Maneuvering Clinical Pathways for Crohn's Disease.

Authors:  Thomas X Lu; Russell D Cohen
Journal:  Curr Gastroenterol Rep       Date:  2019-04-23

7.  Association of HLA-dependent islet autoimmunity with systemic antibody responses to intestinal commensal bacteria in children.

Authors:  Alexandra Paun; Christopher Yau; Shahab Meshkibaf; Michelle C Daigneault; Leili Marandi; Steven Mortin-Toth; Amit Bar-Or; Emma Allen-Vercoe; Philippe Poussier; Jayne S Danska
Journal:  Sci Immunol       Date:  2019-02-01

Review 8.  B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.

Authors:  Mathieu Uzzan; Jean-Frederic Colombel; Andrea Cerutti; Xavier Treton; Saurabh Mehandru
Journal:  Dig Dis Sci       Date:  2016-09-21       Impact factor: 3.199

9.  Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases.

Authors:  Gerard Honig; Caren Heller; Andrés Hurtado-Lorenzo
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325

10.  Epicutaneous Tolerance Induction to a Bystander Antigen Abrogates Colitis and Ileitis in Mice.

Authors:  David Dunkin; M Cecilia Berin; Lucie Mondoulet; Steven Tobar; Garabet Yeretssian; Leticia Tordesillas; Alina Iuga; Thibaut Larcher; Virginia Gillespie; Pierre-Henri Benhamou; Jean-Frederic Colombel; Hugh A Sampson
Journal:  Inflamm Bowel Dis       Date:  2017-11       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.